1. In urinary tract infections which are resistant to co-trimoxazole therapy or other first line agents.

2. Treatment for nosocomial pneumonias, cellulitis or osteomyelitis in sensitive organisms.

3. Oral therapy as an alternative to lengthy intravenous therapy in patients with infections caused by sensitive organisms.

4. Medical prophylaxis in neutropenic and/or bone marrow transplant patients.

5. Patient is past puberty and is not pregnant and meets one of the above criteria.

Monitor:

Elderly patients and patients with hepatic and renal dysfunction.

Xanthine metabolism is inhibited by fluroquinolones.

Concurrent administration of oral heavy metals such as Aluminum, Magnesium and iron decrease absorption of oral quinolones.

Emergence of resistance is likely for pneumococcal infection or in patients with chronic infections.

Seizures (tonic/clonic) are possible with I.V. dosage form.